Publication | Open Access

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

UrologyGenitourinary CancerMedicineImmunologyTumor ImmunityImmune Checkpoint InhibitorRenal Cell CarcinomaCancer TreatmentImmunotherapyOncologyPhase 3